Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
DexCom (DXCM) PT Lowered to $553 at Cowen
February 11, 2022 7:26 AM ESTCowen analyst Joshua Jennings lowered the price target on DexCom (NASDAQ: DXCM) to $553.00 (from $655.00) while maintaining an Outperform rating.
The analyst commented, "After releasing its 4Q21 sales results and 2022 revenue guidance last month, DXCM today reported its full 4Q21 results and provided its 2022... More
DexCom (DXCM) Misses Q4 EPS by 17c
February 10, 2022 4:05 PM ESTDexCom (NASDAQ: DXCM) reported Q4 EPS of $0.68, $0.17 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $698.2 million versus the consensus estimate of $696.47 million.
GUIDANCE:
DexCom sees FY2022 revenue of $2.82-2.94 billion, versus the consensus of $2.96... More
